DexCom jumps as new ADA trial data boosts optimism for broader CGM adoption

DexCom, Inc. (DXCM) is up 5.6% today. Here is some analysis on what might have caused this price movement.

Analysis: DXCM appears to be rising after upbeat clinical results showcased at the American Diabetes Association (ADA) 2026 meeting, highlighting meaningful benefits of continuous glucose monitoring (CGM) for adults with Type 2 diabetes who do not use insulin. Investors may be pricing in a larger addressable market and improved reimbursement momentum if these findings influence future standards of care.

Details:

DexCom announced results from its CONNECT randomized controlled trial, where use of the Dexcom G7 was associated with clinically and statistically significant improvements in glucose control versus routine care using fingerstick testing.

The company highlighted A1C reductions and improvements in “time in range,” including reported benefits across subgroups and across common Type 2 medication regimens.

The trial results were presented as an oral presentation at ADA 2026 in New Orleans (June 5–8, 2026), a major catalyst window for diabetes-device sentiment.

This could also reflect expectations that stronger “level A” style evidence for non-insulin Type 2 patients supports broader coverage and accelerates earlier-stage adoption over time.

Sources:

Business Wire, Dexcom Investor Relations

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$DXCM Insider Trading Activity

$DXCM insiders have traded $DXCM stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.

Here’s a breakdown of recent trading of $DXCM stock by insiders over the last 6 months:

KEVIN R SAYER (Executive Chair) sold 26,759 shares for an estimated $1,926,648
JON COLEMAN (EVP, Chief Commercial Officer) has made 0 purchases and 2 sales selling 9,823 shares for an estimated $722,628.
MICHAEL JON BROWN (EVP, Chief Legal Officer) has made 0 purchases and 3 sales selling 5,100 shares for an estimated $319,260.
BRIDGETTE P HELLER has made 0 purchases and 2 sales selling 2,024 shares for an estimated $129,556.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$DXCM Hedge Fund Activity

We have seen 524 institutional investors add shares of $DXCM stock to their portfolio, and 503 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

WELLINGTON MANAGEMENT GROUP LLP added 6,252,665 shares (+203.4%) to their portfolio in Q1 2026, for an estimated $392,667,362
SANDS CAPITAL MANAGEMENT, LLC removed 4,934,189 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $327,482,123
JENNISON ASSOCIATES LLC removed 4,741,847 shares (-81.9%) from their portfolio in Q1 2026, for an estimated $297,787,991
ALLIANCEBERNSTEIN L.P. added 4,299,512 shares (+49.9%) to their portfolio in Q1 2026, for an estimated $270,009,353
NUVEEN, LLC removed 2,907,804 shares (-62.8%) from their portfolio in Q1 2026, for an estimated $182,610,091
HOLOCENE ADVISORS, LP removed 2,436,672 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $161,721,920
UBS GROUP AG added 2,426,179 shares (+126.1%) to their portfolio in Q1 2026, for an estimated $152,364,041

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$DXCM Congressional Stock Trading

Members of Congress have traded $DXCM stock 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $DXCM stock by members of Congress over the last 6 months:

SENATOR TINA SMITH has traded it 2 times. They made 0 purchases and 2 sales worth up to $500,000 on 05/07, 04/29.
SENATOR JOHN BOOZMAN purchased up to $15,000 on 01/26.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$DXCM Analyst Ratings

Wall Street analysts have issued reports on $DXCM in the last several months. We have seen 2 firms issue buy ratings on the stock, and 1 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 02/13/2026
Barclays issued a "Underweight" rating on 01/12/2026
Mizuho issued a "Outperform" rating on 12/17/2025

To track analyst ratings and price targets for $DXCM, check out Quiver Quantitative's $DXCM forecast page.

$DXCM Price Targets

Multiple analysts have issued price targets for $DXCM recently. We have seen 11 analysts offer price targets for $DXCM in the last 6 months, with a median target of $84.0.

Here are some recent targets:

Jonathan Block from Stifel set a target price of $90.0 on 06/05/2026
Joanne Wuensch from Citigroup set a target price of $84.0 on 05/28/2026
Matt Miksic from Barclays set a target price of $64.0 on 05/18/2026
William Plovanic from Canaccord Genuity set a target price of $82.0 on 05/18/2026
Travis Steed from B of A Securities set a target price of $80.0 on 05/18/2026
Joshua Jennings from TD Cowen set a target price of $75.0 on 05/01/2026
Marie Thibault from BTIG set a target price of $85.0 on 03/09/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.